Biotech turns to new viruses to advance gene therapy; the hazards of clinical research in the Dobbs era

Biotech turns to new viruses to advance gene therapy; the hazards of clinical research in the Dobbs era ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Health insurers are painting a misleading picture of Medicare Advantage savings, experts say By Bob Herman Adobe A new report funded by the insurance industry claims Medicare Advantage saves taxpayers “billions of dollars.” Experts don’t buy it. Read More Opinion: Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era By Aoife Brennan Molly Ferguson for STAT Criminalizing women for their reproductive health choices raises serious issues for clinical research in states that restrict abortion. Read More STAT+: Biotech turns to new and strange viruses to overcome gene therapy's limitations By Jason Mast CDC via AP The hope is that nature’s nanoscale menagerie can be used to solve the safety, durability, and capacity issues in the gene therapy field. Read More Sponsor content by Janssen Research & Development, LLC. How biomarkers have the potential to enhance precision for neurodegenerative disorders The complex biology of neurological disorders has made precision medicine difficult to apply in clinical neuroscience. However, the successful application of biomarkers may help scientists overcome the field's historic R&D obstacles. Janssen is committed to leading the precision revolution in neuroscience not only with new therapeutic entities but also by advancing the understanding and use of biomarkers as tools to transform the way neurodegenerative disorders are identified, treated, and ultimately prevented. Read the article here. Opinion: FDA: Ignore a pharma company's deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug By Adam C. Urato Adobe A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people. Read More Monday, September 26, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser